Assessment of Platelet Function in Traumatic Brain Injury-A Retrospective Observational Study in the Neuro-Critical Care Setting. by Lindblad, Caroline et al.
January 2018 | Volume 9 | Article 151
Original research
published: 26 January 2018
doi: 10.3389/fneur.2018.00015
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Cameron Bass, 
Duke University, 
United States
Reviewed by: 
Ralph George Depalma, 
United States Department of 
Veterans Affairs, United States 
Lucia A. Rivera Lara, 
Johns Hopkins University, 
United States
*Correspondence:
Bo-Michael Bellander 
bo-michael.bellander@ki.se
Specialty section: 
This article was submitted 
to Neurotrauma, 
a section of the journal 
Frontiers in Neurology
Received: 05 June 2017
Accepted: 09 January 2018
Published: 26 January 2018
Citation: 
Lindblad C, Thelin EP, Nekludov M, 
Frostell A, Nelson DW, Svensson M 
and Bellander B-M (2018) 
Assessment of Platelet Function 
in Traumatic Brain Injury—A 
Retrospective Observational Study 
in the Neuro-Critical Care Setting. 
Front. Neurol. 9:15. 
doi: 10.3389/fneur.2018.00015
assessment of Platelet Function  
in Traumatic Brain injury—a 
retrospective Observational study  
in the neuro-critical care setting
Caroline Lindblad1, Eric Peter Thelin1,2, Michael Nekludov3, Arvid Frostell1,  
David W. Nelson3, Mikael Svensson1 and Bo-Michael Bellander1*
1 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 2 Division of Neurosurgery, Department of 
Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom, 
3 Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, 
Stockholm, Sweden
Background: Despite seemingly functional coagulation, hemorrhagic lesion progression 
is a common and devastating condition following traumatic brain injury (TBI), stressing 
the need for new diagnostic techniques. Multiple electrode aggregometry (MEA) mea-
sures platelet function and could aid in coagulopathy assessment following TBI. The 
aims of this study were to evaluate MEA temporal dynamics, influence of concomitant 
therapy, and its capabilities to predict lesion progression and clinical outcome in a TBI 
cohort.
Material and methods: Adult TBI patients in a neurointensive care unit that under-
went MEA sampling were retrospectively included. MEA was sampled if the patient 
was treated with antiplatelet therapy, bled heavily during surgery, or had abnormal 
baseline coagulation values. We assessed platelet activation pathways involving the 
arachidonic acid receptor (ASPI), P2Y12 receptor, and thrombin receptor (TRAP). 
ASPI was the primary focus of analysis. If several samples were obtained, they were 
included. Retrospective data were extracted from hospital charts. Outcome variables 
were radiologic hemorrhagic progression and Glasgow Outcome Scale assessed 
prospectively at 12 months posttrauma. MEA levels were compared between patients 
on antiplatelet therapy. Linear mixed effect models and uni-/multivariable regression 
models were used to study longitudinal dynamics, hemorrhagic progression and out-
come, respectively.
results: In total, 178 patients were included (48% unfavorable outcome). ASPI levels 
increased from initially low values in a time-dependent fashion (p <  0.001). Patients 
on cyclooxygenase inhibitors demonstrated low ASPI levels (p < 0.001), while platelet 
transfusion increased them (p < 0.001). The first ASPI (p = 0.039) and TRAP (p = 0.009) 
were significant predictors of outcome, but not lesion progression, in univariate analyses. 
In multivariable analysis, MEA values were not independently correlated with outcome.
conclusion: A general longitudinal trend of MEA is identified in this TBI cohort, even 
in patients without known antiplatelet therapies. Values appear also affected by platelet 
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inhibitory treatment and by platelet transfusions. While significant in univariate models 
to predict outcome, MEA values did not independently correlate to outcome or lesion 
progression in multivariable analyses. Further prospective studies to monitor coagulation 
in TBI patients are warranted, in particular the interpretation of pathological MEA values 
in patients without antiplatelet therapies.
Keywords: traumatic brain injury, progressive hemorrhagic injury, platelet aggregation, platelet aggregation 
inhibitors, multiple electrode aggregometry, cyclooxygenase inhibitors
inTrODUcTiOn
Traumatic brain injury (TBI) is a worldwide leading cause of 
mortality and disability (1). Following the acute phase, TBI is 
characterized by the development of secondary injuries (1), of 
which one is trauma-induced coagulopathy (TIC) (2). In severe 
TBI, the incidence of coagulopathy exceeds 60% (2) and is asso-
ciated with lesion progression, mortality (3), and poor outcome 
(2). Alarmingly, despite conventional coagulation parameters 
within normal reference intervals, radiologic progression of 
intracranial lesions still occurs among more than 30% of patients 
(4). Moreover, the TBI setting now comprises increasingly older 
patients (5) for which antiplatelet therapy is common (6, 7), but 
associated with lesion progression and unfavorable outcome (7, 8). 
Consequently, hemorrhagic progression is the leading cause of 
seemingly preventable death (9) following TBI. In aggregate, 
there is considerable interest in diagnosis and treatment of coagu-
lopathy in TBI patients, especially in the case of anticoagulative 
therapies.
Diagnosis of coagulopathy is complex (2, 10). Routine platelet 
and coagulation tests comprising platelet count, activated par-
tial thromboplastin time (APTT), and international normalized 
ratio (2, 11) have been shown to be insufficient to diagnose the 
full perspective of coagulopathies (4). Similarly, more advanced 
laboratory tests, including thromboelastography and rotational 
thromboelastometry, do not adequately predict coagulopathy 
(10). Of the aforementioned, platelet count is commonly used 
to assess primary hemostasis and risk for bleeding progression, 
but platelet count is a quantitative measurement that does 
not account for platelet functionality (11). This has led to the 
development of platelet function assessment techniques (12). 
Among the methods described in Ref. (12), Multiplate® (Roche 
Diagnostics, Basel, Switzerland) and VerifyNow® (Accumetrics, 
San Diego, CA, USA) correlate with light transmittance 
aggregometry, the gold standard method for assessing platelet 
function (12).
While these techniques are primarily used to assess platelet 
function in cardiology patients, Multiplate®, based on multiple 
electrode aggregometry (MEA), use was shown to improve out-
come prediction in a general trauma population (13). However, 
in TBI cohorts, the utility of MEA remains to be convincingly 
shown. In spite of this, MEA is used with increasing frequency in 
clinical practice, demonstrating the clinicians’ need to evaluate 
platelet function and improve coagulation assessment within the 
field of TBI.
In our department, a majority of patients with TBI in need 
of neurointensive care unit (NICU) care is assessed using MEA. 
This presents a unique opportunity to evaluate its utility within 
the clinical setting. With this in mind, we sought to character-
ize MEA alterations following TBI, analyze how MEA levels are 
altered in drug induced coagulopathy, examine how MEA levels 
are associated with bleeding progression in patients with severe 
TBI, and how it subsequentially affects outcome.
MaTerials anD MeThODs
This was a retrospective observational study undertaken at the 
NICU at Karolinska University Hospital (Stockholm, Sweden) 
including patients treated between February 2010 (clinical 
introduction of MEA) and May 2014. The work was approved 
by the local ethics committee in Stockholm County, the Central 
Ethical Review Board (diary numbers 2014/1488-31/5 and 
2015/1675-31/1).
study criteria
Patients were included if they had suffered a traumatic intracra-
nial lesion, were of ≥15 years of age, and had been admitted to the 
NICU during the years 2010–2014. All patients included were at 
all times treated according to local routine at the NICU, as earlier 
described in Ref. (14).
Definitions
Trauma severity was assessed using the definitions of the 
Advanced Trauma and Life Support system (15) and is described 
as Injury Severity Score (ISS) (16). CT scans were evaluated by 
a trained examiner, blinded from coagulation measurements 
and outcome. Radiological parameters included midline shift  
(in mm), traumatic subarachnoid hemorrhage, epidural hema-
toma, acute subdural hematoma, and cerebral contusions. CT 
scans were graded according to Ref. (17), Rotterdam CT score 
(18), and Stockholm CT score (19). Stockholm CT score was 
used in the models as it has been shown to be the more accurate 
outcome predictor of these (20). The admission and follow-up CT 
scans were evaluated with regard to radiologic intracranial hem-
orrhagic progression. All types of intra- and extra-parenchymal 
lesions on the follow-up brain CT scan were compared with the 
initial scan and if any progression had occurred, it was noted (14). 
If the patient underwent surgical evacuation of an intracranial 
lesion, any un-evacuated hematomas present were assessed for 
progression. Data including Glasgow Coma Scale (GCS), ISS, 
and outcomes were collected prospectively in the Karolinska 
Traumatic Injury database. Additional parameters were collected 
retrospectively through the electronic medical record system 
TakeCare® (CompuGroup Medical Sweden AB, Farsta, Sweden), 
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and any missing was be interpreted as not performed as there is 
no loss of data within the system.
Outcome
Glasgow Outcome Scale (GOS) (21) was evaluated at approxi-
mately 12  months following the trauma by questionnaire con-
cerning functional outcome. GOS is classified as a categorical 
variable, where GOS 1 indicates death, GOS 2 vegetative state, 
GOS 3 severe dependent state, GOS 4 moderate independent 
state, and GOS 5 full recovery. Dichotomized GOS comprises the 
two categories GOS 1–3 (unfavorable) and GOS 4–5 (favorable) 
outcome.
Mea Measurements
The Multiplate® (Roche Diagnostics, Basel, Switzerland) unit was 
used to assess MEA values. This is an impedance aggregometry 
method (22) where multiple electrodes are immersed in a blood 
sample. Upon initial contact with blood, platelets coat the elec-
trodes. Following stimulation with platelet agonists, there is a large 
increment in platelet aggregation upon the electrodes, quantified 
as increased impedance (23), and measured as an area under the 
curve (AU), providing the measurement unit. The method has 
been previously used in settings comprising intracranial pathol-
ogy (24).
Using MEA, we evaluated three different platelet activation 
pathways: the arachidonic acid receptor (ASPI), P2Y12 receptor 
(ADP), and thrombin receptor (TRAP). These receptors are spe-
cifically inhibited by the pharmacological compounds: cyclooxy-
genase (COX) inhibitors (ASPI), P2Y12 inhibitors (ADP), and 
glycoprotein IIb/IIIa antagonists (TRAP) (23). Indications for 
MEA tests were as follows: antiplatelet therapy; heavy periopera-
tive bleeding judged by the surgeon and/or intensivist; clinical 
bleeding propensity; or abnormal baseline hematologic values. 
MEA tests were occasionally taken solely at the initiative of a cli-
nician. Commonly, if a first sample was obtained and particularly, 
if it guided treatment, the initial measurement was followed by 
subsequent measurements to evaluate treatment effect. Currently, 
there are no internationally established guidelines advising when 
MEA samples should be acquired in NICU TBI patients. In this 
study, up to nine MEA measurements were recorded per patient. 
The “first value” was defined as the value in closest proximity to 
admission. Two different MEA devices (both Multiplate®) were 
used. The reference intervals were similar for the two devices, 
with the exception of ASPI, which was 71–115  AU in a local 
NICU apparatus and 65–119 AU in the central laboratory appa-
ratus. The reference interval for the local apparatus was used in 
further analyses.
statistical analysis
The full statistical protocol is described in the Supplementary 
Materials and Methods in the Supplementary Material. 
Demographic data were presented as mean  ±  SD, median 
(interquartile range), or count (%). Spearman correlation (rho, ρ) 
was used to assess correlation between different platelet recep-
tor values, in addition to visual scatterplots. The distribution of 
MEA was examined using the Shapiro–Wilk test, and inferential 
analysis was conducted using the Mann–Whitney U test and the 
Wilcoxon signed rank test where appropriate. We assessed longi-
tudinal changes of MEA values (ASPI) using linear mixed effect 
models with random and fixed effects in the lme4 package (25) 
in R. Model criteria were evaluated graphically and deemed to be 
fulfilled. The compiled model was obtained using likelihood ratio 
tests, where after the model with the lowest Akaike Information 
Criterion value was chosen. Various outcome prediction models 
were used. First, to assist hypothesis generation, outcome was visu-
alized using recursive partitioning decision trees in the R package 
rpart (26) and rattle (27) with GOS as dependent variable (21). 
Independent variables were those previously shown to be the major 
predictors for TBI outcome [International Mission for Prognosis 
and Analysis of Clinical Trials in TBI (IMPACT) variables] (28), 
combined with coagulation tests clinically available at our clinic, 
including the first MEA values. Regression models were used to 
assess association with outcome (GOS, proportional odds) and 
hemorrhagic progression (logistical). The univariate analysis on 
outcome was performed with unimputed data. Variables included 
in univariate analysis were chosen with guidance from Fabbri and 
colleagues (7), or if hypothesized to modulate platelet function or 
coagulation. Variables emanating significant in univariate analy-
sis were analyzed in a step-up followed by a step-down model, 
ultimately resulting in the final multivariable model using the R 
package rms (29). The statistical software program Rstudio® (R 
Foundation for Statistical Computing, Vienna, Austria; http://
www.R-project.org) was used in all calculations.
Missing Data
Missing values relevant for outcome analysis were plotted (Figure 
S1 in Supplementary Material) using the R package neato (30). As 
several variables contained missing values to a large extent, we 
employed a standard multiple imputation approach using seven 
imputations of the dataset using the R package mice (31). The 
individual imputations and the pooled result from them were 
used in subsequent analyses. This approach has been used by 
the IMPACT study group (32) and is favored by the statistical 
literature (33).
resUlTs
Demographics
Between 2010 and 2014, 387 TBI patients were admitted to the 
NICU at the Karolinska University Hospital. Of these, 178 under-
went MEA analysis and were included. Patient demographics are 
presented in Tables 1 and 2, respectively. Admission GCS varied 
from 3 to 15, with a median GCS of 7 (severe TBI). In total, 48% 
suffered an unfavorable outcome. At hospital admission, 24% 
of the patients had COX inhibitor treatment. The median MEA 
values for the first ASPI and ADP measurements were lower than 
the reference interval, meanwhile the first TRAP measurement 
was within it. Of all patients’ first MEA values, 124 (70%) had 
pathologically low ASPI values, 109 patients (61%) had low ADP, 
and 65 patients (37%) low TRAP values. Throughout the hospital 
stay, 112 patients (63%) received a platelet transfusion, with a 
median total volume of 600 ml.
TaBle 2 | Coagulation status.
Variable Patient values reference 
interval (unit)
Platelet count admission 212 (175–248) 145–348 (109/l)
APTT admission 31 (29–36) 28–40 (s)
Missing 9 (5)
INR admission 1.1 (1–1.2) <1.2 (INR)
Missing 6 (3)
ASPI, first value 51 (23.5–79) 71–115; 65–119 
(AU)
ADP, first value 51 (31–69) 57–113; 57–113 
(AU)
TRAP, first value 95 ± 35.6 84–128; 84–128 
(AU)
Missing 1 (0.56)
Platelet transfusion Transfused 112 (63)
Missing 4 (2)
Platelet transfusion dose Volume 600 (0–1,142) (ml)
Missing 10 (5.6)
Erythrocyte transfusion Transfused 102 (57)
Fresh frozen plasma 
transfusion
Transfused 80 (45)
COX inhibitor treatment Treatment 
before 
admission
42 (24)
ADP inhibitor treatment Treatment 
before 
admission
5 (2.8)
In total, 178 patients were included. Data are depicted as count (%) if categorical 
and otherwise as median (interquartile range), or mean ± SD, if continuous. When 
applicable, reference intervals are reported as those that at the time point of the 
study were used at the Karolinska University Hospital. Measurement units are given in 
parentheses next to the reference interval value. MEA measurements were obtained 
using two different devices, which had slightly different reference intervals, both of 
which are reported.
ADP, P2Y12 receptor; APTT, activated partial thromboplastin time; ASPI, arachidonic 
acid receptor; AU, area under the curve; COX, cyclooxygenase; INR, international 
normalized ratio; TRAP, thrombin receptor; MEA, multiple electrode aggregometry.
TaBle 1 | Patient demographics.
Variable Type (unit) Total number of 
patients: 178
Gender Male/female 133/45 (75/25)
Age (years) 54 (37–65)
Oxygen saturation SoA (%) 96 (93–98)
Missing 68 (38)
Blood pressure SoA Systolic (mmHg) 130 (120–150)
Missing 69 (39)
Admission GCS GCS 3 53 (30)
GCS 4–5 15 (8)
GCS 6–8 31 (17)
GCS 9–13 47 (26)
GCS 14–15 32 (18)
Median 7
Pupil responsiveness 
admission
Normal 138 (78)
Unilateral unresponsive 18 (10)
Bilateral unresponsive 19 (11)
Missing 3 (1.7)
Extracranial injury 
(multitrauma)
Present 46 (26)
Radiological findings Midline shift (mm) 3 (0–9)
Progression hematoma 60 (34)
Epidural hematoma 20 (11)
Dual subdural hematoma 11 (6)
Intraventricular bleeding 28 (16)
Subarachnoid hemorrhage basal 
cisterns
42 (24)
Subarachnoid hemorrhage 
convexity
121 (68)
Stockholm CT score Total score 22 ± 9.6
Final GOS GOS 1 (dead) 22 (12)
GOS 2 (vegetative) 2 (1)
GOS 3 (severe, dependent) 61 (34)
GOS 4 (moderate, independent) 56 (31)
GOS 5 (recovered) 37 (21)
GOS 1–3 (unfavorable) 85 (48)
GOS 4–5 (favorable) 93 (52)
In total, 178 patients were included. Data are depicted as count (%) if categorical and 
otherwise as median (interquartile range) or mean ± SD, if continuous. If there were any 
missing values, they are denoted as count (%) after each variable of concern.
GCS, Glasgow Coma Scale; GOS, Glasgow Outcome Scale; SoA, scene of accident.
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correlation between Different  
Mea Variables
There was a significant positive correlation between all three 
platelet receptors’ first MEA values (Figures S2A1–C1 in 
Supplementary Material). For the ASPI versus TRAP receptor, 
ρ = 0.59 (p < 0.001). For the ASPI versus ADP receptor, ρ = 0.71 
(p  <  0.001). Finally, for the ADP versus the TRAP receptor, 
ρ = 0.66 (p < 0.001). Based on this, we pursued our examinations 
primarily using the ASPI receptor.
Platelet Modulating Pharmacological 
compounds
The first MEA values were examined on 127 patients of which 30 
had received COX inhibitor treatment. We excluded all patients 
who had received a platelet transfusion before MEA values were 
obtained. MEA values were lower for patients treated with COX 
inhibitors compared with those who were not (Figure  1A), 
p < 0.001. Notably, the median ASPI value was below the lower 
reference interval, independent of COX inhibitor therapy. 
In total, ~66% of patients without COX inhibitor treatment demo-
nstrated ASPI values below the lower reference interval. MEA 
values increased following a platelet transfusion (Figure  1B), 
p < 0.001.
longitudinal Pattern
Immediately following TBI, platelet function (ASPI) was 
low and thereafter increased over time (Figure  2A; Table  3, 
p <  0.001). The same graphical trend was seen when exclud-
ing patients on COX inhibitors (Figure S3B in Supplementary 
Material), or that had been transfused with platelets (Figure S3C 
in Supplementary Material). Moreover, platelet count was posi-
tively correlated with MEA values (Figure S4 in Supplementary 
Material; Table 3, p < 0.001). Patients presenting with ongoing 
COX inhibitor treatment had consistently lower ASPI values 
than patients not treated with COX inhibitors (Figure  2A; 
Table 3, p = 0.026), except for one time point, which, however, 
was preceded by an increase in the number of platelet transfu-
sions (Figure 2B).
FigUre 1 | Pharmacologic modulation of multiple electrode aggregometry (MEA) values. The first arachidonic acid receptor (ASPI) values (indicated as individual 
data points and as summarizing boxplots) for a subset of patients with and without cyclooxygenase (COX) inhibitor treatment (and without preceding platelet 
transfusions) are depicted (a). Overall, COX inhibitor treatment yielded lower ASPI results, p < 0.001. In panel (B), a subgroup of patients who had undergone MEA 
measurements before and after transfusion were selected. Individuals are plotted with their respective ASPI value at the first and second measurement, with a line 
connecting each individual. No account was taken for how long time that had passed between the first and second MEA measurement, but there was still a strongly 
significant (p < 0.001) increase in platelet function following transfusion.
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Mea as Predictor of hemorrhagic 
Progression and Outcome
Outcome Illustration Using Decision Trees
The decision tree gives a graphic representation of information 
content that could aid rule based interpretation of the data. 
Decision trees from all seven imputations were compared visu-
ally and showed congruency overall (data not shown), of which 
one representative is shown (Figure  3). Low first ASPI values 
appear to distinguish worse outcome in patients <68 years with 
higher GCS (≥5.5) scores at admission. Although already on level 
three of the decision tree, this degree of subgrouping must be 
interpreted with care and as hypothesis generating.
Regression Analyses of MEA versus Outcome  
and Hemorrhagic Progression
Relations of MEA values toward GOS levels were visualized with 
conditional density plots (CD plots, Figures 4A–C). ASPI values 
had a u-shaped relation to GOS (Figure 4A), where both high 
and low levels were associated with a more unfavorable outcome. 
Although areas with limited data must be interpreted with cau-
tion, the CD plots can help visualize the information content, 
and accuracy of univariate regression will be related to the slope 
of the lines discriminating levels in areas with most data. ADP 
showed a similar tendency as ASPI, but fluctuations probably 
reflecting “noise,” make interpretation difficult (Figure  4B). 
Higher TRAP values were visually associated with favorable 
GOS (Figure 4C). The results of the univariate analysis (Table 4) 
were congruent with the CD plots, with ASPI (p = 0.0389) and 
TRAP (p = 0.0086), but not ADP being significantly related to 
GOS. The IMPACT variables (28) that form the “base model” 
[age, admission GCS, pupil responsiveness, Stockholm CT score, 
oxygen saturation, and blood pressure (BP)] were significant 
in univariate analysis with the exception of BP. Additional 
significant variables in univariate analysis were the coagula-
tion predictors APTT (p =  0.0020), COX inhibitor treatment 
(p = 0.0176), platelet transfusion (p = 0.0030), and intracranial 
radiologic hemorrhagic progression (p =  0.0001). The ISS was 
not significantly related to outcome. Following step-up (Table S1 
in Supplementary Material) and step-down models, radiologic 
intracranial hemorrhagic progression was the only significant 
variable aside from the base model in the multivariable model 
(Table  5). Overall, the Nagelkerke’s pseudo-R2 had a mean of 
39.8% of the pseudo- explained variance of outcome prediction, 
for the seven different imputations. Since elderly patients are 
more likely to have COX inhibitors, the age variable in IMPACT 
FigUre 2 | Platelet function alterations over time following TBI, dependent on prehospital cyclooxygenase (COX) inhibitor treatment. Patients with COX inhibitor 
treatment before hospital admission demonstrated a consistently lower arachidonic acid receptor (ASPI) value compared with those without COX inhibitor treatment 
(a), as showed by the two LOWESS curves. The black dashed line denotes the ASPI reference interval (71–115 AU). At one time point, however, there was a partial 
overlap, which, as shown in panel (B), might be explained by an increase in platelet transfusions at the time point preceding the overlapping LOWESS curves in 
panel (a). Abbreviations: AU, area under the curve; LOWESS, locally weighted scatterplot smoother; TBI, traumatic brain injury.
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might affect the interpretation of COX inhibitors. Omitting age 
from the base model resulted in COX inhibitors being a signifi-
cant predictor of worse outcome in the multivariable model (data 
not shown).
Relations of MEA as predictors toward hemorrhagic progres-
sion were visualized with CD plots (Figures 4D–F) suggesting 
ASPI values to have a u-shaped association with an increased 
percentage of hemorrhagic progression (Figure 4D), similar to 
GOS. However, this was not significant in univariate analysis 
(Table S2 in Supplementary Material). APTT was significant in 
univariable analysis (p = 0.0178, Nagelkerke’s pseudo-R2 = 0.058, 
Table S2 in Supplementary Material). Admission GCS and 
Stockholm CT score were borderline significant in univariate 
analysis (Table S2 in Supplementary Material). Since no variables 
were significant except APTT, no step-down or multivariable 
analysis was conducted.
TaBle 3 | Linear mixed effect model for ASPI values among TBI patients.
Fixed effect variable estimate se pValue (likelihood ratio test)
Time from trauma 0.10627 0.02 <0.001
Platelet count 0.09221 0.01381 <0.001
COX inhibitor −9.47869 4.23748 0.02583
Random intercepts: p < 0.001 [p value generated using (34)].
AIC value final model: 3,265.7.
Variables affecting ASPI values were compared across measurement time points. 
Variables that affected ASPI when examined graphically were included in the model.  
p Values were obtained using the likelihood ratio test, or as otherwise reported. 
Included random effects were random intercepts (subject ID), presented at the bottom 
of the table.
AIC, Akaike Information Criterion; ASPI, arachidonic acid receptor; COX, 
cyclooxygenase; TBI, traumatic brain injury.
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DiscUssiOn
To the best of our knowledge, this is the first study to investigate 
the clinical utility of a platelet function method in a clinical TBI 
setting. We found that
 (i) Platelet function, as indicated by MEA, exhibits a temporal 
profile even in the absence of platelet inhibitors where MEA 
values are generally low initially, and subsequently increase 
over the days following TBI. If this also reflects a clinically 
significant coagulopathy is yet unknown.
 (ii) The first ASPI and TRAP values were associated with long-
term outcome in univariable analyses, albeit they did not 
contribute with any independent information when adjust-
ing with known outcome predictors.
 (iii) Radiologic intracranial hemorrhagic progression, an 
important predictor of long-term outcome, could not be 
predicted using MEA values.
 (iv) MEA may in part be able to identify patients who arrive with 
TBI using COX inhibitors from a general coagulopathy.
Trauma-induced coagulopathy, one of the secondary injuries 
following TBI, is a poorly defined condition incorporating a 
hypo- and a hypercoagulable state (2). The pathophysiology is 
considered distinct from coagulopathy following other types of 
trauma, due to brain-specific features, e.g., high tissue factor levels, 
interaction between the disrupted blood–brain barrier/plasma 
proteins, and microparticle influence (35, 36). New methods to 
diagnose TIC have gained clinical interest, in particular platelet 
dysfunction, observed following TBI in both studies of animal 
models (37, 38) and human subjects without platelet inhibitory 
treatment (13, 38–41).
Platelet receptor values have but rarely (39) been character-
ized longitudinally following TBI. Numerous studies claim that 
trauma itself induces coagulopathy [reviewed in Ref. (35)]. Here, 
we saw that ~66% of the patients who had not received any COX 
inhibitor treatment exhibited pathologically low ASPI values upon 
admission, as defined by current reference levels. This finding is 
consistent with previous studies on coagulopathy prevalence in 
severe TBI (2). We show a longitudinal alteration of MEA values, 
with initially low values, followed by a later increase. This is con-
sistent with a previous study (39), however, we measured over a 
longer time period and quantified the relationship longitudinally. 
The increase in MEA values was also observed in the absence of 
platelet transfusions, implying that this is a biological phenom-
enon reflecting a trauma-induced alteration of MEA values. This 
finding highlights the need for future studies to investigate MEA 
relations to clinically significant bleeding in TBI patients, even in 
the absence of platelet inhibitors. In addition, cutoff values and 
cutoffs related to elapsed time need to be established. In sum-
mary, this is the first quantitative examination of how MEA values 
alter following TBI.
In outcome analysis, CD plots of GOS and intracranial hemor-
rhagic progression exhibited a similar u-shaped relation between 
ASPI/GOS and ASPI/intracranial hemorrhagic progression, with 
both high and low levels suggesting worse outcomes. This implies 
that there might be ASPI values that are optimal to evade hemor-
rhagic progression and accordingly, affect GOS. However, these 
data should be interpreted cautiously, as the CD plots contained 
few observations at very low and high levels of ASPI. In univariate 
analysis (dependent variable GOS), both the first ASPI and TRAP 
values were significant. In multivariable analysis, this effect was 
no longer seen, meaning that ASPI and TRAP are meaningful for 
outcome prediction per se, but that they do not provide independ-
ent information when one has access to other base line variables. 
An interpretation of this is that pathological ASPI and TRAP 
values reflect a significant coagulopathy that could be related 
to deterioration and thus lower GCS. Prospective and clinician-
blinded studies will be needed to confirm this. Previous studies 
show conflicting results. In one study, the TRAP, and ASPI recep-
tors were independent predictors of mortality (39). In another 
study, unfortunately unadjusted for confounders, ADP and 
TRAP values were different between survivors and non-survivors 
in a mixed trauma population (13). Yet others have found ADP, 
but not ASPI, to be a predictor of mortality (41). Finally, there are 
also studies without relation between platelet function results and 
outcome, hemorrhagic progression, or mortality (42). The lack of 
congruency between these studies, including ours, indicates that 
there is a pressing need for future prospective studies on patients 
with severe TBI.
Radiologic intracranial hemorrhagic progression was a strong 
predictor of GOS. However, in univariate analysis of predictors 
for radiologic hemorrhagic progression, APTT at admission 
was the only significant variable. GCS and Stockholm CT score 
at admission were borderline significant, implying that a worse 
initial clinical status was associated with future progression and 
deterioration. The finding of APTT is interesting, but not the 
focus of this study.
Platelet inhibitors are common among TBI patients due to 
demographic alterations (5, 43). We found consistently lower 
ASPI values among patients on COX inhibitor treatment, congru-
ent with others (39, 43). As has been similarly shown (43), the 
median ASPI was below the reference interval also for patients 
without known COX inhibitor treatment, making it difficult to 
distinguish pharmacologic from trauma-induced platelet recep-
tor hypofunction. In outcome analysis COX inhibitor treatment 
was significantly related to GOS in univariate analysis, but not 
against radiologic intracranial hemorrhagic progression. In 
multivariable analysis, COX inhibitor treatment was no longer 
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FigUre 3 | Continued
FigUre 4 | Depiction of univariate analysis of selected variables hypothesized to influence Glasgow Outcome Scale (GOS) or hemorrhagic progression. In panels 
(a–c), conditional density (CD) plots for the different platelet receptors versus GOS are demonstrated. In a CD plot, the left y-axis depicts the category of the 
dependent variable (in this case GOS). The right y-axis depicts outcome proportions for each value of the x-axis’ independent variable (in this case the different 
platelet receptors). The red line overlaid in the plot depicts the amount of observations across different values of the independent variable and has therefore no 
relation with the y-axis. As the density plot demonstrates, there were fewer patients with extreme values of the independent variable, respectively, thus decreasing 
the reliability of the relationship between the independent variable and GOS at these values of the independent variable. In panel (a), arachidonic acid receptor 
(ASPI) values generated high amounts of unfavorable outcome (GOS 1–3) at low and high ASPI values, respectively, although there was scarce amount of data for 
higher ASPI values. The same trend was not readily detectable for the P2Y12 receptor (ADP) due to a fluctuating curve (B) but was evident for the TRAP (c).  
In panels (D–F), CD plots for the different platelet receptors versus hemorrhagic progression are depicted. A similar u-shaped relation as in panels (a–c) was 
detected for ASPI but now toward increased risk of hemorrhagic progression (D). A similar trend was seen in (e) but not as readily in panel (F), depicting the P2Y12 
(ADP) receptor and thrombin receptor (TRAP), respectively.
FigUre 3 | A decision tree for determining the importance of ASPI. A representative imputation of one of the decision trees is depicted. Each node in the tree 
denotes the predicted GOS value (indexed by color and GOS category number), followed by the percentage of patients belonging in each node. While moving 
downwards in the tree, GOS changes depending on the independent variables and the percentages of patients who pertain to the stipulated criteria decrease 
accordingly. Consistent across all imputations, ASPI values in the range of 32–68 affected the determination of Glasgow Outcome Scale (GOS) 4–5 among younger 
patients with higher GCS (only one imputation shown). Radiologic score was defined as the Stockholm CT score (19). Data values are presented in the same units 
as can be found in Tables 1 and 2, respectively. Abbreviations: adm, admission; ADP, P2Y12 receptor; ASPI, arachidonic acid receptor; BP, blood pressure; GCS, 
Glasgow Coma Scale; ISS, Injury Severity Score; SoA, scene of accident; TRAP, thrombin receptor; #, ordered number of sample; GOS, Glasgow Outcome Scale.
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significant. COX inhibitor treatment has previously been shown 
to predict worsening lesions on follow-up radiology (7) and 
to predict unfavorable outcome [reviewed in Ref. (11)]. Other 
studies have failed to demonstrate this (42). As the majority of 
patients on COX inhibitor treatment are older, when adjusting 
for age, the true effect of the treatment might disappear. When we 
TaBle 5 | Multivariable proportional odds analysis of variables affecting final 
GOS.
independent variable Or ci pValue
Age 0.966 0.948–0.984 0.000117
GCS admission 1.130 1.05–1.21 0.001612
Pupil responsiveness 0.596 0.355–1.00 0.0707
Stockholm CT score 0.945 0.914–0.977 0.00176
Oxygen saturation SoA 1.06 1.00–1.11 0.0685
Blood pressure SoA 1.00 0.992–1.01 0.409
Radiological intracranial 
hemorrhagic progression
0.363 0.196–0.671 0.00479
Mean Nagelkerke’s pseudo-R2 0.398 = 39.8%
Results from multivariable analysis of independent variables assumed to affect Glasgow 
Outcome Scale (GOS) are depicted. Data are presented as odds ratio (OR) and 95% 
confidence interval (CI) for one imputation. p Values are reported as the pooled p value 
from all imputations (n = 7).
CT, computerized tomography; GCS, Glasgow Coma Scale; SoA, scene of accident.
TaBle 4 | Univariate analysis of variables and correlations to final GOS.
independent variable pValue Pseudo-R2
Base model
Age 0.0008 0.067
GCS at admission <0.0001 0.167
Pupil responsiveness 0.0070, <0.0001 0.130
Stockholm CT score <0.0001 0.208
Oxygen saturation at SoA 0.0282 0.044
Blood pressure at SoA 0.1401 NS
additional variables assessed
Injury Severity Score 0.4317 NS
ASPI, 1st value 0.0389 0.026
ADP, 1st value 0.2874 NS
TRAP, 1st value 0.0086 0.042
TPK at admission 0.3616 NS
INR at admission 0.4198 NS
APTT at admission 0.0020 0.060
Platelet transfusion 0.0030 0.054
COX inhibitor treatment 0.0176 0.034
Radiologic intracranial hemorrhagic progression 0.0001 0.104
Results from univariate analysis of independent variables assumed to affect Glasgow 
Outcome Scale (GOS) are depicted. Apart from the IMPACT variables (28), these 
comprised platelet count, coagulation measurements, variables hypothesized to 
modulate platelet function, and radiologic intracranial hemorrhagic progression. 
Platelet transfusion, COX inhibitor treatment, and radiologic intracranial hemorrhagic 
progression were used as dichotomous variables.
ADP, P2Y12 receptor; APTT, activated partial thromboplastin time; ASPI, arachidonic 
acid receptor; COX, cyclooxygenase; CT, computerized tomography; GCS, Glasgow 
Coma Scale; INR, international normalized ratio; SoA, scene of accident; TRAP, 
thrombin receptor.
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conducted the analysis omitting age adjustment, COX inhibitor 
treatment was a predictor of worse outcome, leading us to believe 
that not only could this account for previous discrepancies, but 
also, that until convincingly shown in a prospective randomized 
material, COX inhibitor treatment should be considered a risk 
factor for worse prognosis.
A theoretical treatment for platelet dysfunction is platelet 
transfusion. Based on ASPI levels, we distinguished an increased 
platelet function following transfusion, as expected (8). In out-
come analysis, platelet transfusion was as a predictor of worse 
outcome in univariate, but not multivariable, analysis. These 
results should be interpreted very cautiously, since a group more 
heavily transfused often is one with more extensive injuries, and 
patients diagnosed with a hemorrhagic progression might have 
received transfusions to a larger extent than those who were not. 
Therefore, we cannot claim that transfusions are inadvisable. 
Yet, the implementation of MEA has resulted in diagnosis of 
presumptive pathology, for which there is no widely acknowl-
edged treatment regimen (39). A review of five retrospective 
TBI studies where patients had antiplatelet therapy before 
admission found both beneficial and harmful effects of platelet 
transfusion therapy (44), whereas platelet transfusion was not 
significantly associated with outcome in later studies (45). In 
conclusion, the clinical value of platelet transfusions in the 
treatment of TIC therefore remains to be convincingly shown 
and especially in the setting of pathological MEA values in 
patients not receiving platelet inhibitors. Notably, the AABB 
(formerly the American Association of Blood Banks) could 
not recommend either for or against platelet transfusion for 
the subgroup of patients on antiplatelet therapy and traumatic 
intracranial hemorrhage (46).
This study should be pursued by a blinded randomized pro-
spective multicenter study on isolated (non-multitrauma) TBI 
patients using GOS and lesion progression as outcome variables. 
MEA measurements should be taken at fixed, consecutive time 
points. Using these data, it would be possible to establish eligible 
reference intervals at different time points and conduct outcome 
analysis.
limitations
This study holds all the limitations of a retrospective study. 
Residual confounding, confounding by indication, and treatment 
bias must be assumed to exist in our data. These highlight prob-
lems with retrospective observational analyses and emphasize the 
need for blinded prospective trials. However, in lack of such MEA 
is often performed as a screening to identify if unconscious TBI 
patients are on platelet inhibitors. This will present the physician 
with a multitude of pathological MEA values in patients without 
platelet inhibitors, and without a metric for interpretation. This 
highly motivates an observational study such as this, despite its 
retrospective nature. Moreover, despite caveats, this is one of the 
first and larger studies to analyze a large cohort of mild-to-severe 
TBI patients and as we have had access to large amounts of pro-
spectively collected data, we believe our data set is clinically valid 
for an NICU TBI population. Further, we have access to some 
unique variables like the trauma time, successfully registered 
in all prehospital records. Importantly, we have used this for a 
reliable characterization of platelet function longitudinally, which 
can rarely be done in equally large materials elsewhere. Still, 
MEA samples were to a large extent obtained at different time 
points, and treatments given at others. Moreover, our assessment 
of intracranial hemorrhage progression could be a bit sensitive 
as any lesion present was taken into account. Previous studies 
have defined set threshold, such as a minimal blood volume of 
2 ml on the first CT scan (47). Further, we did not account for 
concomitant infection or disseminated intravascular coagulation 
(DIC) (48), both of which, but in particular DIC (48–50) could 
have confounded our data. This is complicated by the fact that it 
is difficult to distinguish between different types of coagulopathy 
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following TBI (50). Altogether, we have been able to statistically 
compensate for some of the lack of standardization in our het-
erogeneous data set. Yet, the nature of our data and study design 
limits the extent to which conclusions can be drawn from this 
cohort, and our findings should at this point be seen as hypothesis 
generating. In aggregate, this study represents a large data set 
from a clinical setting that many physicians will be presented 
with and that will require decisions. This highly motivates this 
retrospective hypothesis generating study in wait of blinded 
prospective studies.
cOnclUsiOn
We present the first larger investigation of the clinical utility of 
platelet function measurements using MEA in NICU treated 
TBI patients. Following TBI, a general longitudinal trend, with 
initially low MEA values and a subsequent increase over days 
is seen, indicating a pathophysiological link. MEA levels were 
affected by both COX inhibitor treatment and platelet transfu-
sion. Progression of intracranial hemorrhage is an important 
predictor of poor TBI prognosis but MEA values could not 
significantly predict this condition. Both ASPI and TRAP values 
were associated with outcome, but did not add any independent 
information in presence of other outcome predictors. In sum-
mary, these findings warrant further prospective, blinded trials 
to full understand the utility of MEA in TBI patients.
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